Navigation Links
Superior mesenteric artery syndrome in a diabetic patient

Diabetes mellitus is one of the most common chronic disease of the world and the prevalence of diabetes mellitus is over 10% in Taiwan. Gastroparesis is reported in 5% to 12% of diabetic patients. Superior mesenteric artery (SMA) syndrome is an uncommon disease resulting compression of the third portion of the duodenum from the superior mesenteric artery. However, SMA syndrome can cause the same symptoms as diabetic gastroparesis.

A research team, led by Dr. Wen-Ming Wang from Kaohsiung Medical University Hospital reported a rare etiology of superior mesenteric artery syndrome. Their study will be published on December 21, 2009 in the World Journal of Gastroenterology.

Their report suggest that diabetic patients with gastrointestinal symptoms and bodyweight loss should be considered for SMA syndrome, despite the gastroparesis is the most common etiology. Computed tomography and upper gastrointestinal series are the reliable tools for diagnosis. Adequate nutrition supply is a useful treatment and the aim is bodyweight gain and symptom relief. Surgery is indicated when conservative treatment fails.


Contact: Ye-Ru Wang
World Journal of Gastroenterology

Page: 1

Related medicine news :

1. Houston Northwest Medical Centers Patient Outcomes Superior
2. Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study
3. In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack
4. Superior Dental Care Alliance Launches Maximum Advantage Program
5. Data Show ARIMIDEX(R) (Anastrozole) Continues To Be Superior to Tamoxifen in Helping Reduce the Risk of Recurrence in Patients With Early Breast Cancer
6. Companys Award-Winning Sound Enhancement Technology Proven to Provide Superior Performance Over Other Technologies; Patent Will Enhance Able Planet, LINX AUDIO Brands
7. Digital mammography superior to film mammography in some cases
8. A Drug With Efficacy Superior to That of Memantine Would Earn up to a 50% Patient Share in the Moderate-to-Severe Alzheimers Disease Drug Market
9. Video: TI unveils industrys first family of complete analog front ends for superior ultrasound systems
10. Superior Customer Service Imperative During Economic Downturn
11. Promising early evidence of the superior benefits of drug therapy for diabetic eye disease
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015—Since the start ... scientific research and discoveries, leading us to better understand the disease’s behavior. Globally, ... affected by HIV/AIDS. Mediaplanet’s cross-platform edition of “World AIDS Day” provides insight on ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... amputations in the United States. Podiatrists are well aware that psychology-based patient non-compliance ... behaviors) are often catastrophic contributors to diseases of the diabetic foot. The ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates mobile imaging results ... subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they are demonstrating new ... America (RSNA) 2015 annual meeting through December 3 in Chicago, Illinois, at Booth ...
(Date:12/1/2015)... MA (PRWEB) , ... December 01, 2015 , ... Lutronic, ... release of Clarity, the latest addition to the devices for sale in the United ... 755 nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , a leader ... leadership since 2008. Gary Bruce, President of PartnerTech North America, currently serves as ... significant amount of time in Sweden since joining PartnerTech based in Malmo, Sweden. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Dec. 1, 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... chronic pain, announced today that the company will present at ... December 1-3 at the Luxe Sunset Boulevard Hotel in ... CEO of Relmada Therapeutics, will present on Thursday, December 3, ... . Please register at least 10 minutes prior ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... , Dec. 1, 2015  Today, ... the launch of CareFront, a first-of-its-kind population health ... diagnosed with cancer. Designed to be built into ... cancer patients with resources for their care and ... program also offers tools to help patients understand ...
Breaking Medicine Technology: